Kajian Profil Pengobatan pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda Tahun 2020

Study of Medication Profile in COVID-19 Patients at Hospital X Samarinda City in 2020

Authors

  • Himmatul Ulya Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia
  • Noviyanty Indjar Gama Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia
  • Islamudin Ahmad Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia

DOI:

https://doi.org/10.25026/mpc.v17i1.692

Abstract

COVID-19 atau Coronavirus Disease 2019 merupakan penyakit penyebab infeksi Severe Acute Respiratory Syndrom (SARSCoV-2) yang menyerang saluran pernapasan hingga organ lain pada manusia. Proses transmisi yang cukup tinggi antar manusia menyebabkan virus ini bergerak cepat menyebar dan ditetapkan sebagai pandemi. Hingga saat inipun masih belum ada pengobatan spesifik terkait infeksi SARSCoV-2, sehingga tatalaksana pengobatan yang dilakukan dengan menggunakan terapi simptomatik sesuai gejala, terapi suportif untuk pencegahan komplikasi serta pengobatan sesuai komorbid. Penelitian ini bertujuan untuk mengetahui karakteristik pasien serta profil pengobatan pada pasien COVID-19 di Rumah Sakit X Kota Samarinda tahun 2020. Metode pengumpulan data dilakukan secara retrospektif berdasarkan catatan rekam medis pasen COVID-19 selama periode Januari hingga Desember tahun 2020. Hasil penelitian menunjukkan bahwa dari 95 pasien penderita COVID-19 didominasi oleh laki-laki (52,63%), mayoritas berusia 26 – 45 tahun (40%), tidak memiliki penyakit penyerta (73,68%) dan lama perawatan selama 7 – 14 hari (51,58%). Hasil penelitian pada profil pengobatan pasien COVID-19 diperoleh terapi suportif terbanyak Antivirus Oseltamivir (6,54%), Antibiotik Azithromycin (6,45%), Antikoagulan Fondapurinux Na (1,55%), Vitamin Becomzet® (2,58%) dan terapi simptomatik terbanyak Gangguan Pencernaan Omeprazole (4,99%), Mukolitik Asetilsistein (7,49%), Analgesik dan Antipiretik Paracetamol (4,82%), Kortikosteroid Dexamethasone (1,72%).

References

Lukito J. I., 2020. “Tinjauan Antivirus untuk Terapi COVID-19,” Cermin Dunia Kedokt., vol. 47, no. 7, pp. 340–345, doi: 10.55175/cdk.v47i7.595.

Morfi C. W., Junaidi, A., Elsesmita, E., Asrini, D. N., Lestari, D. M., Medison, I., Russilawati, R., Fauzar, F., Kurniati. R and Yani, F. F., 2020. “Kajian Terkini CoronaVirus Disease 2019 (COVID-19),” J. Ilmu Kesehat. Indones., vol. 1, no. 1, pp. 1–8, doi: 10.25077/jikesi.v1i1.13.

Sciaccaluga, C., Cameli, M., Menci, D., Mandoli, G. E., Sisti, N., Cameli, P., Franchi, F., Mondillo, S and Valente, S., 2021. “COVID-19 and the burning issue of drug interaction: Never forget the ECG,” Postgrad. Med. J., vol. 97, no. 1145, pp. 180–184, doi: 10.1136/postgradmedj-2020-138093.

WHO, 2023. Coronavirus disease (COVID-19). https://covid19.who.int/region/searo/country/id (accessed Jan. 01, 2023).

Keputusan Menteri Kesehatan Republik Indonesia, 2020. “Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19),” MenKes/413/2020, p. 1-136.

Fried, M. W., Crawford, J. M., Mospan, A. R., Watkins, S. E., Munoz, B., Zink, R. C., Elliott, S., Burleson, K., Landis, C., Reddy, K.R and Brown JR, R. S., 2021. “Patient Characteristics and Outcomes of 11,721 Patients with COVID-19 Hospitalized Across the United States,” Clin. Infect. Dis., vol. 72, no. 10, pp. 558–565, pp.e558-e565.

für das Alter N. A., 2020. “Risikofaktor Komorbi-ditäten bei COVID-19-Erkrankung,” Pneumologie, vol. 74, pp. 639–640, 2020.

Wardani, E. M., Bistara, D. N. and Septianingrum, Y., 2022. “Karakteristik klinis dan lama rawat inap pasien covid-19 dengan kormobid dan tanpa kormobid,” Holistik J. Kesehat., vol. 15, no. 4, pp. 666–673, doi: 10.33024/hjk.v15i4.5761.

Mukherjee, S and Pahan, K., 2021. “Is COVID-19 Gender-sensitive?,” J. Neuroimmune Pharmacol., vol. 16, pp. 38–47.

Illah, M. N. N., 2021. “Analisis Pengaruh Komorbid, Usia, dan Jenis Kelamin Terhadap Meningkatnya Angka Kematian pada Masa Pandemi Covid-19,” J. Sos. Sains, vol. 1, no. 10, pp. 1228–1233, doi: 10.36418/sosains.v1i10.232.

Jamini, T., 2021. “Gambaran Lama Hari Rawat Inap Pasien Covid-19 Berdasarkan Karakteristik Demografi, Klinis dan Hasil Laboratorium Pasien di Ruang Perawatan Covid-19 RSUD H. Boejasin Pelaihari Tahun 2021,” J. Penelit. UPR, vol. 1, no. 2, pp. 1–9, doi: 10.52850/jptupr.v1i2.4086.

Masrika, N. U. E., Hasan, M., Yusran, Y and Buyung, S., 2022. “Karakteristik Pasien COVID-19 di Rumah Sakit Umum Daerah Dr. H. Chasan Boesoirie,” JUMANTIK (Jurnal Ilm. Penelit. Kesehatan), vol. 7, no. 3, pp. 255–265, doi: 10.30829/jumantik.v7i3.11676.

Al-omari, A., Alhuqbani, W. N., Zaidi, A. R. Z., Al-Subaie, M. F., Alhindi, A. M., Abogosh, A. K., Alrasheed, A. K., Alsharafi, A. A., Alhuqbani, M. N., Salih, S and Alhedaity, M. A., 2020. “Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia?: A descriptive cross-sectional study,” J. Infect. Public Health, vol. 13, no. 11, pp. 1639–1644, doi: 10.1016/j.jiph.2020.09.003.

Seftiya, A. and Kosala, K., 2021. “Epidemiologi Karakteristik Pasien Covid-19 di Kalimantan Utara,” J. Sains dan Kesehat., vol. 3, no. 5, pp. 645–653, doi: 10.25026/jsk.v3i5.542.

Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M and Eggo, R. M., 2020. “Age-dependent effects in the transmission and control of COVID-19 epidemics,” Nat. Med., vol. 26, no. 8, pp. 1205–1211, doi: 10.1038/s41591-020-0962-9.

Hidayani, W. R., 2020. “Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19?: Literature Review,” J. Untuk Masy. Sehat, vol. 4, no. 2, pp. 120–134.

Prasetyawan, I. P. F., Imron, M., I kurnia Wulansari, A and Prihartini, I., 2021. “Profil Peresepan Terapi Obat COVID-19 Pada Pasien Rawat Inap Tanpa Komorbid di Rumah Sakit Umum Daerah Gambiran Kota Kediri,” Java Heal. J., vol. 8, no. 3, pp. 1–5.

Ruhama, R. S., Mahmudah, F. and Sastyarina, Y., 2021. “Karakteristik Pasien Terkonfirmasi Coronavirus disease (COVID-19) di RS X Samarinda Periode Maret-Desember 2020,” Proceeding Mulawarman Pharm. Conf., vol. 14, pp. 262–266, doi: 10.25026/mpc.v14i1.582.

Pepitasari, B. D and Anggraini, T. D., 2021. “Gambaran Tatalaksana Terapi Pada Pasien COVID-19 Terkonfirmasi di Rumah Sakit X Kota Surakarta Periode Maret-Desember 2020,” Indones. J. Med. Sci., vol. 8, no. 2, pp. 119–126.

Agustiyah, L. and Ronoatmodjo, S., 2021. “Karakteristik Pasien Terkonfirmasi Covid-19 Di Rsud Al-Mulk Kota Sukabumi Periode September 2020 - Juni 2021,” J. Keperawatan dan Kebidanan, vol. 4, no. 2, pp. 158–169.

Hill, M. A., Mantzoros, C and Sowers, J. R., 2020. “Commentary: COVID-19 in patients with diabetes,” Metab. Clin. Exp., vol. 107, pp. 1–2, doi: 10.1016/j.metabol.2020.154217.

Sandooja, R., Vura, N. V. R. K. and Morocco, M., 2020. “Heightened ACE Activity and Unfavorable Consequences in COVID-19 Diabetic Subjects,” Int. J. Endocrinol., pp. 1–5, 2020, doi: 10.1155/2020/7847526.

Elemam, N. M., Hannawi, H., Al Salmi, I., Naeem, K. Bin., Alokaily, F and Hannawi, S., 2021. “Diabetes mellitus as a comorbidity in COVID-19 infection in the United Arab Emirates,” Saudi Med. J., vol. 42, no. 2, pp. 170–180, doi: 10.15537/SMJ.2021.2.25700.

Wu, S., Xue, L., Legido-Quigley, H., Khan, M., Wu, H., Peng, X., Li, X and Li, P., 2020. “Understanding factors influencing the length of hospital stay among non-severe COVID-19 patients: A retrospective cohort study in a Fangcang shelter hospital,” PLoS One, vol. 15, no. 10, pp. 1–14, doi: 10.1371/journal.pone.0240959.

Maharianingsih, N. M., Sudirta, I. K. and Suryaningsih, N. P. A. 2022. “Karakteristik Pasien dan Penggunaan Obat Pada Pasien Covid-19 Derajat Sedang Hingga Berat,” Indones. J. Pharm. Educ., vol. 2, no. 2, pp. 101–109, doi: 10.37311/ijpe.v2i2.13958.

Fahmia, R., Helda, H. and Nursari, A. Y., 2022. “Lama Rawat Inap Pasien Terkonfirmasi COVID-19 di Rumah Sakit Universitas Indonesia dan Faktor yang Mempengaruhinya,” J. Epidemiol. Kesehat. Indones., vol. 6, no. 1, pp. 1–12, doi: 10.7454/epidkes.v6i1.5004.

Zhao, W., Zha, X., Wang, N., Li, D., Li, A. and Yu, S., 2021 “Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study,” Cardiovasc. Innov. Appl., vol. 6, no. 1, pp. 1–23, doi: 10.15212/cvia.2021.0019.

Wu, Y., Hou, B., Liu, J., Chen, Y., and Zhong, P., 2020. “Risk Factors Associated With Long-Term Hospitalization in Patients With COVID-19: A Single-Centered, Retrospective Study,” Front. Med., vol. 7, no. 6, pp. 1–10, doi: 10.3389/fmed.2020.00315.

Wasiaturrahmah, Y., Perdana Putra, A. M., Nahdha, N. and Rahmah, N., 2022. “Profil Penggunaan Obat Pada Pasien Covid-19 Di Salah Satu Rumah Sakit Di Banjarmasin,” J. Insa. Farm. Indones., vol. 5, no. 1, pp. 149–158, doi: 10.36387/jifi.v5i1.917.

Kusumawardani, A. L., Maria, N. and Fanani, N. Y., 2021. “Potential drug interactions analysis of COVID-19 patients at a hospital in West Java Analisis potensi interaksi obat pada pasien rawat inap COVID-19 pada suatu rumah sakit di Jawa Barat,” J. Ilm. Farm. (Scientific J. Pharmacy), vol. 17, no. 2, pp. 181–196.

Setiadi, A. P., Wibowo, Y. I., Halim, S. V., Brata, C., Presley, B. and Setiawan, E., 2020. “Tata Laksana Terapi Pasien dengan COVID-19: Sebuah Kajian Naratif,” Indones. J. Clin. Pharm., vol. 9, no. 1, pp. 70–94, doi: 10.15416/ijcp.2020.9.1.70.

Burhan E., Susanto, A. D., Isbaniah, F., Nasution, S. A., Ginanjar, E., Pitoyo, C. W., 2020. Pedoman Tatalaksana COVID-19, 3rd ed. Jakarta, PDPI, PERKI, PAPDI, PERDATIN, IDAI.

Lisni, I., Mujianti, D. and Anggriani, A., 2021. “Antibiotic Profile For Covid-19 Treatment in a Hospital in Bandung,” J. Ilm. Farm. Bahari, vol. 12, no. 2, pp. 99–106, doi: 10.52434/jfb.v12i2.1196.

Kangdra, W. Y., 2021. “Karakteristik Klinis dan Faktor Komorbid pada Pasien dalam Pengawasan (PDP) Coronavirus Disease 2019 (COVID-19) di RS Mitra Medika Amplas,” Sumatera Utara, [Online]. Available: http://repositori.usu.ac.id/handle/123456789/30672.

Beigelman, A., Isaacson-Schmid, M., Sajol, G., Baty, J., Rodriguez, O. M., Leege, E., Lyons, K., Schweiger, T. L., Zheng, J., Schechtman, K. and Castro, M., 2015. “Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis,” J. Allergy Clin. Immunol., vol. 135, no. 5, pp. 1171–1178, doi: 10.1016/j.jaci.2014.10.001.

Cai, M., Bonella, F., Dai, H., Sarria, R., Guzman, J. and Costabel, U., 2013. “Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia,” Immunobiology, vol. 218, no. 6, pp. 930–937, doi: 10.1016/j.imbio.2012.10.014.

Zarogoulidis, P., Papanas, N., Kioumis, I., Chatzaki, E., Maltezos, E. and Zarogoulidis, K., 2012. “Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases,” Eur. J. Clin. Pharmacol., vol. 68, no. 5, pp. 479–503, doi: 10.1007/s00228-011-1161-x.

Chih, C. L., Cheng, Y. W., Po-ren, H., 2020. “Co-infections among patients with COVID- 19?: The need for combination therapy with non-anti-SARS-CoV-2 agents??,” J. Microbiol. Immunol. Infect., vol. 53, no. 4, pp. 505–512, doi: 10.1016/j.jmii.2020.05.013.

Cong, W. Poudel, A. N., Aihusein, N., Wang, H., Yao, G. and Lambert, H., 2021. “Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS-CoV-2 Pandemic?: A Scoping Review,” Antibiotics, vol. 10, no. 6, pp. 1–14.

Riedel, S., Morse, S., Mietzner, T., Miller, S., 2019. Jawetz, Melnick, & Adelberg’s Medical Microbiology, 28th ed. New York: McGrawHill.

Calder, P. C., Carr, A. C. and Gombart, A. F., 2020. “Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections,” Nutrients, vol. 12, pp. 1–10.

Hasan, M., Levani, Y., Laitupa, Y. and Triastuti, N., 2021. “Pemberian Terapi Vitamin C pada COVID-19,” J. Pandu Husada, vol. 2, no. 2, p. 74, doi: 10.30596/jph.v2i2.5754.

Kurniawan, D., 2022. “Evaluasi Penggunaan Obat pada Pasien COVID-19 di Rumah Sakit Umum Rawat Inap Sultan Imanuddin Pangkalan BUN Periode Januari-Desember 2021,” p. 104, [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders.

Pratiwi, A. D. E and Adhityasmara, D., 2021. “Gambaran Penggunaan Antikoagulan Pada Pasien Covid-19 Di Salah Satu Rumah Sakit Rujukan Covid-19 Di Kota Semarang,” Sebatik, vol. 25, no. 2, pp. 442–448, doi: 10.46984/sebatik.v25i2.1619.

Cui, S., Chen, S., Li, X., Liu, S. and Wang, F., 2020. “Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia,” J. Thromb. Haemost., vol. 18, no. 6, pp. 1421–1424, doi: 10.1111/jth.14830.

Kollias, A., Kyriakoulis, K. G., Dimakakos, E., Poulakou, G., Stergiou, G. S. and Syrigos, K., 2020. “Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action,” Br. J. Haematol., vol. 189, no. 5, pp. 846–847, doi: 10.1111/bjh.16727.

Santoliquido, A., Porfidia, A., Nesci, A., De Matteis, G., Marrone, G., Porceddu, E., Camma, G., Giaretta, I., Fantoni, M., Landi, F., Gasbarrini, A., Pola, R., D'Alfonso, M. E. and Lo Monaco, M. R., 2020. “Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis,” J. Thromb. Haemost., vol. 18, no. 9, pp. 2358–2363, doi:

1111/jth.14992.

Levani, Y. P and Mawaddatunnadila., 2021. “Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi,” J. Kedokt. dan Kesehat., vol. 17, no. 1, pp. 44–57.

Ramadani, L., Hidayat, N. and Fauzia, D., 2016. “Gambaran Penggunaan Analgetik pada Pasien Rawatan Intensif di RSUD Arifin Achmad Provinsi Riau Periode Januari-Desember 2015,” J. Online Mhs. Bid. Kedokt., vol. 4, no. 2, pp. 1–23.

Sujana, K. S. and Maulida, M., 2021. “Efektivitas N-Acetylsistein pada Pasien COVID-19,” Cermin Dunia Kedokt., vol. 48, no. 7, pp. 416–418.

Wicaksono, A. G., Pambudi, R. S. and Septiana, R., 2022. “Treatment Patterns of Covid-19 in Patients at Indriati Boyolali Hospital,” Pancasakti J. Public Heal. Sci. Res., vol. 2, no. 3, pp. 208–217, doi: 10.47650/pjphsr.v2i3.563.

Ardyati, S., Kurniawan, N. U. and Darmawan, E., 2017. “Pengaruh Pemberian Steroid sebagai Terapi Tambahan terhadap Rata-Rata Lama Pasien Dirawat di Rumah Sakit dan Tanda Klinis pada Anak dengan Pneumonia,” J. Farm. Klin. Indones., vol. 6, no. 3, pp. 181–189, doi: 10.15416/ijcp.2017.6.3.181.

The Recovery Collaborative Group., 2021. “Dexamethasone in Hospitalized Patients with Covid-19,” N. Engl. J. Med., vol. 384, no. 8, pp. 693–704, doi: 10.1056/nejmoa2021436.

Bruton, L., Chabner, L. B. A and Knollman, B. C., 2014. “Drugs Affecting Gastrointestinal Function,” in Goodman & Gillman’s The Pharmacological Basic of Therapeutics, 12th ed., L. Brunton, L, Ed. New York: McGrawHill, p. 1037.

Aguila, E. J. T. and Cua, I. H. Y., 2020. “Repurposed GI Drugs in the Treatment of COVID ? 19,” Dig. Dis. Sci., vol. 65, no. 8, pp. 2452–2453, doi: 10.1007/s10620-020-06430-z.

Bimantara, D. E., 2020. “Peran Vitamin C dalam Pengobatan COVID-19”. Jurnal Majority., vol. 9, no. 1, pp. 123-125.

Downloads

Published

2023-06-30

How to Cite

Ulya, H., Gama, N. I., & Ahmad, I. (2023). Kajian Profil Pengobatan pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda Tahun 2020: Study of Medication Profile in COVID-19 Patients at Hospital X Samarinda City in 2020. Proceeding of Mulawarman Pharmaceuticals Conferences, 17(1), 67–78. https://doi.org/10.25026/mpc.v17i1.692

Issue

Vol. 17 (2023): Proc. Mul. Pharm. Conf.

Section

Articles

License

Copyright (c) 2023 Proceeding of Mulawarman Pharmaceuticals Conferences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)

1 2 3 > >>